23andMe to Report FY2023 Third Quarter Monetary Outcomes
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (23andMe), a number one human genetics and biopharmaceutical firm with a mission to assist folks entry, perceive, and profit from the human genome, introduced as we speak that it’ll report monetary outcomes for the fiscal yr 2023 (FY2023) third quarter after the market closes on Wednesday, February 8, 2023. The Firm will webcast a convention name at 4:30 p.m. Jap Time on that date to debate the quarter’s monetary outcomes and report on enterprise progress.
The webcast might be accessed on the day of the occasion at https://traders.23andme.com/news-events/events-presentations. A webcast replay might be accessible on the similar deal with for a restricted time inside 24 hours after the occasion.
As well as, 23andMe will use the Say Applied sciences platform to permit retail and institutional shareholders to submit and upvote inquiries to administration prematurely of the earnings convention name. Beginning as we speak, shareholders can submit questions by visiting https://app.saytechnologies.com/23andme-2023-q3. The Q&A platform will stay open till 24 enterprise hours earlier than the earnings name.
23andMe is a genetics-led shopper healthcare and therapeutics firm empowering a more healthy future. For extra data, please go to investors.23andme.com.
This press launch incorporates forward-looking statements inside the which means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended, together with, with out limitation, statements concerning the long run efficiency of 23andMe’s companies in shopper genetics and therapeutics and the expansion and potential of its proprietary analysis platform. All statements, aside from statements of historic truth, included or included on this press launch, together with statements concerning 23andMe’s technique, monetary place, funding for continued operations, money reserves, projected prices, plans, and targets of administration, are forward-looking statements. The phrases “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “might,” “might,” “ought to,” “potential,” “probably,” “tasks,” “predicts,” “proceed,” “will,” “schedule,” and “would” or, in every case, their adverse or different variations or comparable terminology, are supposed to determine forward-looking statements, though not all forward-looking statements include these figuring out phrases. These forward-looking statements are predictions primarily based on 23andMe’s present expectations and projections about future occasions and numerous assumptions. 23andMe can’t assure that it’ll truly obtain the plans, intentions, or expectations disclosed in its forward-looking statements and you shouldn’t place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements contain a lot of dangers, uncertainties (lots of that are past the management of 23andMe), or different assumptions which will trigger precise outcomes or efficiency to vary materially from these expressed or implied by these forward-looking statements. The forward-looking statements contained herein are additionally topic typically to different dangers and uncertainties which are described occasionally within the Firm’s filings with the Securities and Alternate Fee, together with beneath Merchandise 1A, “Danger Components” within the Firm’s most up-to-date Annual Report on Type 10-Ok, as filed with the Securities and Alternate Fee, and as revised and up to date by our Quarterly Reviews on Type 10-Q and Present Reviews on Type 8-Ok. The statements made herein are made as of the date of this press launch and, besides as could also be required by legislation, 23andMe undertakes no obligation to replace them, whether or not because of new data, developments, or in any other case.
Investor Relations Contact: [email protected]
Media Contact: [email protected]